Valuation : Interpace Biosciences, Inc.

Market Cap 4.22Cr 3.64Cr 3.41Cr 3.11Cr 5.86Cr 403.37Cr 5.88Cr 40Cr 16Cr 203.62Cr 16Cr 16Cr 675.17Cr P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 4.09Cr 3.52Cr 3.3Cr 3.02Cr 5.68Cr 390.74Cr 5.7Cr 39Cr 15Cr 197.24Cr 15Cr 15Cr 654.02Cr EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
8.77%
Yield 2024 *
-
Yield 2025 -
1 day+5.08%
1 week+0.05%
Current month+0.44%
1 month-1.86%
3 months-15.36%
6 months-14.60%
Current year+23.85%
1 week 6.5
Extreme 6.5
7.85
1 month 6.5
Extreme 6.5
8.5
Current year 5.15
Extreme 5.15
12
1 year 3.85
Extreme 3.85
12
3 years 2.22
Extreme 2.216625
17.7
5 years 2.22
Extreme 2.216625
51.65
10 years 2.22
Extreme 2.216625
990
Manager TitleAgeSince
Chief Executive Officer 64 01/12/2020
Director of Finance/CFO 34 21/04/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 21/06/2016
Director/Board Member 73 01/01/2016
Director/Board Member 64 22/01/2020
Date Insider Type Main position Quantity % Market Cap.
20/08/26 Free

Director

69,252 0.2501%
20/08/26 Fiscal year

Chief Financial Officer

13,85,045 5.0015%
20/08/26 Free

Director

69,252 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
+5.08%+0.05%+84.68%+49.37% 4.22Cr
-3.67%-1.74%+94.34%+487.75% 4.7TCr
-0.21%-0.37%+21.73%+57.89% 2.72TCr
-0.30%-4.93%-16.15%-37.78% 710.47Cr
-1.00%-2.88%+3.93%+134.99% 587.16Cr
-0.27%+1.95%+16.22%+76.62% 337.55Cr
-3.26%-0.84%-33.07%+1,921.90% 257.47Cr
-3.17%+6.30%+150.35%+30.70% 231.9Cr
+1.02%+1.02%+29.25%+25.80% 196.96Cr
-1.93%-12.54%-14.69%-54.48% 188.8Cr
Average -0.77%-0.92%+33.66%+269.28% 993.51Cr
Weighted average by Cap. -2.06%-1.38%+53.22%+304.62%

Financials

2024 2025
Net sales 4.69Cr 4.04Cr 3.79Cr 3.46Cr 6.52Cr 448.49Cr 6.54Cr 45Cr 18Cr 226.4Cr 18Cr 17Cr 750.69Cr 3.87Cr 3.34Cr 3.13Cr 2.86Cr 5.38Cr 370.14Cr 5.4Cr 37Cr 14Cr 186.84Cr 15Cr 14Cr 619.54Cr
Net income 67.02L 57.75L 54.15L 49.43L 93.12L 64Cr 93.41L 6.42Cr 2.51Cr 32Cr 2.52Cr 2.46Cr 107.21Cr 2.46Cr 2.12Cr 1.99Cr 1.81Cr 3.41Cr 234.87Cr 3.43Cr 24Cr 9.19Cr 118.56Cr 9.23Cr 9.03Cr 393.13Cr
Net Debt 43.95L 37.87L 35.51L 32.41L 61.06L 42Cr 61.26L 4.21Cr 1.64Cr 21Cr 1.65Cr 1.61Cr 70Cr -13.22L -11.39L -10.68L -10L -18.37L -13Cr -18.43L -1.27Cr -49.44L -6.38Cr -49.63L -48.55L -21Cr
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
28/26/28 $7.618 +5.08% 2,520
26/26/26 $7.250 +2.11% 1,420
25/26/25 $7.100 -0.70% 1,299
24/26/24 $7.150 -6.09% 402
21/26/21 $7.614 -5.42% 1,965

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXG.D Stock